Target intelligence / Profile preview

T cell receptor alpha joining 10 (TRAJ10)

Target
TRAJ10
Molecular classification
Receptor (T cell receptor gene segment), Immunoglobulin superfamily (as part of TCR), Other (gene segment, not a protein or standalone receptor)
01

Overview

T cell receptor alpha joining 10 (TRAJ10) is a specific joining (J) gene segment within the human T cell receptor (TCR) alpha (TRA) locus. TCRs are heterodimeric surface receptors on T lymphocytes responsible for recognizing antigenic peptides bound to major histocompatibility complex (MHC) molecules[1][2]. The diversity of antigen recognition is generated by somatic recombination of variable (V), joining (J), and constant (C) gene segments for the alpha chain. TRAJ10 is one of approximately 61 J segments available for recombination in the alpha chain locus, contributing to the hypervariable complementarity determining region 3 (CDR3) that directly binds the antigen–MHC complex[2][1]. By itself, TRAJ10 is not a therapeutic target, receptor, or protein but is a constituent gene element foundational for TCR repertoire diversity[1][2]. Key clarification: - TRAJ10 is a gene segment *within* the T cell receptor alpha locus, not a standalone protein or receptor. Its sole biological role is as a recombinatorial component of the TCR alpha chain in developing T lymphocytes, essential for proper immune functioning but not druggable or directly connected to any existing therapeutics or biomarker strategies[1][2]. If you are searching for information on the full T cell receptor or its therapeutic targeting, it may be more appropriate to look for "T cell receptor alpha/beta complex" or "TCR complex" as the canonical target entity[1].

Other names
TRAJ10T cell receptor alpha locus J segment 10TCR alpha J10TCRα J10
02

Biological functions

Immune response (as a necessary genomic segment for functional TCR alpha chain formation)Antigen recognition (indirectly, as a recombined gene segment for specificity)
03

Disease associations

Other (no direct, isolated disease association—rather contributes to T cell diversity relevant to cancer, infection, autoimmunity as part of the full TCR complex)

Beyond the preview

Go deeper on T cell receptor alpha joining 10 (TRAJ10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 10 (TRAJ10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call